ES2167546T3 - Mejoras introducidas en composiciones organicas. - Google Patents

Mejoras introducidas en composiciones organicas.

Info

Publication number
ES2167546T3
ES2167546T3 ES96904957T ES96904957T ES2167546T3 ES 2167546 T3 ES2167546 T3 ES 2167546T3 ES 96904957 T ES96904957 T ES 96904957T ES 96904957 T ES96904957 T ES 96904957T ES 2167546 T3 ES2167546 T3 ES 2167546T3
Authority
ES
Spain
Prior art keywords
improvements introduced
organic compositions
granules
carbomero
preferibly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96904957T
Other languages
English (en)
Inventor
Peter Williams Dettmar
Paul Andrew Dickson
Frank Chadwick Hampson
Ian Gordon Jolliffe
William Peers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reckitt Benckiser Healthcare UK Ltd
Original Assignee
Reckitt Benckiser Healthcare UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reckitt Benckiser Healthcare UK Ltd filed Critical Reckitt Benckiser Healthcare UK Ltd
Application granted granted Critical
Publication of ES2167546T3 publication Critical patent/ES2167546T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Dental Preparations (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCRIBEN GRANULOS MUCOADHESIVOS QUE INCLUYEN A) UN CARBOMERO Y/O UNA SAL DEL MISMO; Y B) UNA CARGA INERTE. LOS GRANULOS PREFERIBLEMENTE INCLUYEN UN AGENTE FARMACEUTICAMENTE ACTIVO QUE RESULTA ADECUADO PARA UNA LIBERACION CONTROLADA EN EL INTERIOR DEL TRACTO GASTROINTESTINAL, O PARA UN LIBERACION DIRIGIDA EN LA MUCOSA GASTROINTESTINAL.
ES96904957T 1995-03-13 1996-03-05 Mejoras introducidas en composiciones organicas. Expired - Lifetime ES2167546T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9505032.4A GB9505032D0 (en) 1995-03-13 1995-03-13 Improvements in or relating to organic compositions

Publications (1)

Publication Number Publication Date
ES2167546T3 true ES2167546T3 (es) 2002-05-16

Family

ID=10771122

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96904957T Expired - Lifetime ES2167546T3 (es) 1995-03-13 1996-03-05 Mejoras introducidas en composiciones organicas.

Country Status (20)

Country Link
US (1) US6306789B1 (es)
EP (1) EP0814771B1 (es)
JP (1) JPH11501652A (es)
KR (1) KR19980702970A (es)
CN (1) CN1126533C (es)
AT (1) ATE212539T1 (es)
AU (1) AU712464B2 (es)
BR (1) BR9607234A (es)
CZ (1) CZ274497A3 (es)
DE (1) DE69618934T2 (es)
ES (1) ES2167546T3 (es)
GB (2) GB9505032D0 (es)
HU (1) HUP9900800A3 (es)
MX (1) MX9706992A (es)
NO (1) NO974194L (es)
NZ (1) NZ302741A (es)
PL (1) PL184407B1 (es)
TR (1) TR199700943T1 (es)
WO (1) WO1996028141A1 (es)
ZA (1) ZA962012B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047128A1 (en) * 1998-03-19 1999-09-23 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
GB9809347D0 (en) * 1998-05-05 1998-07-01 Reckitt & Colmann Prod Ltd Compositions
IN190017B (es) * 1999-01-25 2003-05-31 Panacea Biotech Ltd
AU2002221412B2 (en) 2000-12-05 2006-04-13 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
WO2003007913A2 (en) * 2001-07-20 2003-01-30 Samir Mitragotri Method for oral drug delivery
US6572889B1 (en) * 2002-03-07 2003-06-03 Noveon Ip Holdings Corp. Controlled release solid dosage carbamazepine formulations
US7198653B2 (en) 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US9138414B1 (en) 2006-09-15 2015-09-22 Delavau Llc Calcium supplement having enhanced absorption
US20120027855A1 (en) 2007-07-06 2012-02-02 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
WO2009008006A2 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
EP2942053A1 (en) 2007-07-06 2015-11-11 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
DK3354276T3 (da) * 2007-11-13 2020-03-30 Meritage Pharma Inc Sammensætninger til behandlingen af gastrointestinal inflammation
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
WO2009132050A2 (en) 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
WO2010011605A2 (en) 2008-07-21 2010-01-28 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
EP2328553B1 (en) 2008-08-20 2020-06-10 The Regents of The University of California Corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
AU2014237970B2 (en) * 2013-03-15 2017-01-05 Cook Medical Technologies Llc Adhesive medical products and methods for treating gastrointestinal lesions
US11931227B2 (en) 2013-03-15 2024-03-19 Cook Medical Technologies Llc Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding
EP3328898B8 (en) 2015-07-28 2024-04-10 6452728 Canada Corp. Trkb or trkc agonist compositions and methods for the treatment of otic conditions
EP3478269A4 (en) 2016-06-29 2020-04-08 Otonomy, Inc. OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES
US11452798B2 (en) 2017-09-27 2022-09-27 Cook Medical Technologies Llc Crosslinking submucosal injectate system
WO2019140012A1 (en) 2018-01-09 2019-07-18 Otonomy, Inc. Growth factor otic formulations
WO2019154895A1 (en) 2018-02-08 2019-08-15 Strekin Ag Gel formulation for preventing or treating hearing loss
CN114904007B (zh) * 2022-04-24 2024-04-05 南京紫鸿生物科技有限公司 一种提高卡波姆的堆积密度的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60237054A (ja) 1984-05-10 1985-11-25 Nippon Kayaku Co Ltd アミノ酸の晶析法
GB8428952D0 (en) 1984-11-16 1984-12-27 Beecham Group Plc Formulations
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
US5057317A (en) 1987-03-24 1991-10-15 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
EP0297866A3 (en) 1987-07-01 1989-12-13 The Boots Company PLC Therapeutic agents
GB9010039D0 (en) * 1990-05-03 1990-06-27 Reckitt & Colmann Prod Ltd Medicament preparation
DE4036757A1 (de) * 1990-11-17 1992-05-21 Bayer Ag Antazida-zubereitung mit verlaengerter magenverweilzeit
TW209174B (es) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
US5350584A (en) * 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
EP0995447A1 (en) * 1993-09-09 2000-04-26 Takeda Chemical Industries, Ltd. Formulation comprising antibacterial substance and antiulcer substance

Also Published As

Publication number Publication date
KR19980702970A (ko) 1998-09-05
DE69618934T2 (de) 2002-09-12
ATE212539T1 (de) 2002-02-15
PL322065A1 (en) 1998-01-05
DE69618934D1 (de) 2002-03-14
GB2298790A (en) 1996-09-18
CZ274497A3 (cs) 1998-03-18
US6306789B1 (en) 2001-10-23
AU4886896A (en) 1996-10-02
EP0814771A1 (en) 1998-01-07
GB9604678D0 (en) 1996-05-01
HUP9900800A3 (en) 2001-02-28
NO974194D0 (no) 1997-09-11
GB2298790B (en) 1999-06-30
MX9706992A (es) 1997-11-29
ZA962012B (en) 1996-09-26
CN1178458A (zh) 1998-04-08
WO1996028141A1 (en) 1996-09-19
AU712464B2 (en) 1999-11-04
JPH11501652A (ja) 1999-02-09
NZ302741A (en) 1999-08-30
TR199700943T1 (xx) 1998-02-21
HUP9900800A2 (hu) 1999-07-28
PL184407B1 (pl) 2002-10-31
GB9505032D0 (en) 1995-05-03
EP0814771B1 (en) 2002-01-30
BR9607234A (pt) 1997-11-11
HK1011291A1 (en) 1999-07-09
NO974194L (no) 1997-09-11
CN1126533C (zh) 2003-11-05

Similar Documents

Publication Publication Date Title
ES2130423T3 (es) Sistema de administracion intravaginal.
NO974194D0 (no) Forbedringer i, eller vedrörende, organiske sammensetninger
NL301005I2 (nl) Aliskiren of een farmaceutisch aanvaardbaar zout daarvan; en hydrochloorthiazide of een farmaceutisch aanvaardbaar zout daarvan
ES2091737T1 (es) Formulados farmaceuticos de fluoxetina.
ES2159591T3 (es) Composicion de liberacion controlada.
ES2081531T3 (es) Composiciones farmaceuticas que contienen rifaximina para el tratamiento de infecciones vaginales.
NO20016108L (no) Kontrollert frigivelse og smaks maskerende orale farmasöytiske sammensetninger
DE60143393D1 (de) Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
CO5680109A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
PA8508701A1 (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
IT1264451B1 (it) 3-(carbossimetossifenil)-benzofuran-2-oni come agenti stabilizzanti
ES2157975T3 (es) Soluciones farmaceuticas con solubilidad mejorada.
ES2050070B1 (es) Procedimiento para la preparacion de una composicion destinada a la liberacion prolongada y controlada de una substancia peptidica.
CL2008002407A1 (es) Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04).
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
ES2101082T3 (es) Composiciones de liberacion controlada.
IT1275816B1 (it) Composizioni farmaceutiche solide per uso vaginale
NO994431L (no) Ny formulering
NO983530L (no) Dihydrobenzofuran og relaterte forbindelser anvendelig som anti-inflammatoriske midler
AR019699A1 (es) Composicion farmaceutica para el tratamiento de disfuncion de la evacuacion y uso de la misma para la preparacion de un agente terapeutico
ATE478662T1 (de) Arzneilösungen enthaltend modafinilverbindungen
ES2124983T5 (es) Utilizacion de un antagonista de substancia p para el tratamiento de las manchas rojas cutaneas de origen neurogeno.
ES2062527T3 (es) Preparacion oral que puede ser liberada en una region apropiada del intestino.
AR005970A1 (es) Compuestos de benzotiofeno y formulaciones farmaceuticas que los contienen como agente activo
AR046402A1 (es) Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio